About this trial
Ivonescimab is an investigational bispecific antibody, which may simultaneously block two separate targets in the body; blocking these targets may decrease the cancer cells ability to live, grow, and spread. The purpose of this phase 3 clinical trial is to measure overall survival (OS) and safety of ivonescimab when combined with chemotherapy compared to pembrolizumab combined with chemotherapy.
Eligible patients who are enrolled on this clinical trial will be randomly assigned to one of two treatment groups. Half the patients will be assigned to receive ivonescimab and chemotherapy and the other half will receive pembrolizumab and chemotherapy.
Patient Profile
You may be eligible if you have been diagnosed with metastatic NSCLC and you have not received any prior therapy for NSCLC in the metastatic setting. You cannot have any known actionable genomic alterations which include EGFR, ALK, ROS1.
Where’s this trial being run?
Beaumont Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | HARMONi-3 |
|---|---|
| Number: | 24-24 |
| Full Title: | Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients |
| Principal Investigator: | Prof Jarushka Naidoo |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Summit Therapeutics |
| Recruitment Started: |
Global: 11-Aug-2023 Ireland: 29-Oct-2024 |
| Global Recruitment Target: | 400 |
|---|---|
| Ireland Recruitment Target: | 12 |